Caprion-HistoGeneX Expands its Histological Biomarker Franchise by Joining Forces with Mosaic Laboratories
MONTREAL, Jan. 12, 2021 /PRNewswire/ - Caprion-HistoGeneX, a leading global contract research laboratory services provider backed by Arsenal Capital Partners ("Arsenal"), announced today the acquisition of Mosaic Laboratories LLC ("Mosaic"), a California-based company offering histology and immunohistochemistry services to global pharmaceutical clients. The addition of Mosaic further strengthens the North American base for Caprion-HistoGeneX's histopathology assay development and deployment, expands the volume of pathology services and consolidates the company's position as a world-leading service provider of histopathology biomarker analysis for global clinical trials.
Mosaic is a pioneer in using multiplex immunohistochemistry with spectral imaging and is recognized for its outstanding services for the development, validation and implementation of complex immunohistochemistry, in situ hybridization and FISH assays, positioning itself as one of the most prominent and comprehensive providers in the field. Core Mosaic capabilities include study design, assay development and deployment, data interpretation, and services to support exploratory biomarker analysis at pre-clinical and clinical trial stages, thereby enabling timely decisions for patient selection.
"We are truly excited to join forces with Caprion-HistoGeneX. This partnership provides strong collaboration opportunities that will further support the programs of our clients and allow us to globalize our existing and future assays to support clinical trials," said Chris Kerfoot and Lisa Dauffenbach, Co-founders and Managing Members of Mosaic.
"The combination of Mosaic and Caprion-HistoGeneX strengthens our leadership position as a global provider of precision medicine services offering the full range of immunohistochemistry, immune monitoring, proteomics and genomics biomarkers" said Martin LeBlanc, CEO of Caprion-HistoGeneX. "Mosaic's excellent track record of developing and deploying complex immunohistochemistry assays will improve our ability to meet the rapidly expanding needs of our clients for histopathology services across our global network of laboratories in North America, Europe, and Asia, including China."
"The addition of Mosaic reflects Arsenal's commitment to support the development and international expansion of Caprion-HistoGeneX through continued investment in complementary capabilities, services and geographic coverage, and solidifies the company's leadership position in one of the fastest growing areas of biopharma R&D." said David Spaight, the Executive Chairman of Caprion-HistoGeneX and an Operating Partner of Arsenal.
In conjunction with this transaction and the recently announced acquisition of Clinical Logistics Inc., Caprion-HistoGeneX is also planning to unveil in the coming weeks its new corporate name and brand identity for the combined entities reflecting its vision and positioning as a leading global provider of precision medicine services.
Kirkland & Ellis LLP acted as legal advisors to Caprion-HistoGeneX.
Intrepid Investment Bankers LLC acted as financial advisor, and Davis Wright Tremaine LLP acted as legal advisor to Mosaic.
About Mosaic Laboratories LLC
About Arsenal Capital Partners
View original content to download multimedia:http://www.prnewswire.com/news-releases/caprion-histogenex-expands-its-histological-biomarker-franchise-by-joining-forces-with-mosaic-laboratories-301205838.html
SOURCE Caprion Biosciences